Why Clinical Digital Out-of-Home Displays Are Healthcare’s Most Untapped Advertising Opportunity

Here is the central absurdity of clinical Digital Out-of-Home (DOOH): screen owners have constructed the most intentful advertising environment in healthcare — a captive, health-focused audience, sitting with a specific medical concern occupying their full attention, within minutes of a clinical conversation that could change their treatment — and they are being paid for it at roughly the same Cost per Mille (CPM) as channels that cannot guarantee a human was in the room.

That is not a minor pricing inefficiency. It is a categorical misevaluation. And it persists not because the inventory lacks value, but because the infrastructure to prove that value has lagged behind the inventory itself.

That gap is closing. What happens when it does will reprice the entire category.

The audience no other channel can guarantee

Consider what clinical screens actually offer. A patient checks in for a cardiology follow-up. They sit down. For the next twenty-plus minutes, they are present, attentive, and thinking about one thing. There is no second screen. No ability to skip. No ambient distraction competing for attention. Just a patient, a health concern, and a display — in proximity, in context, in the moment.

Compare that to the environment where pharmaceutical brands currently concentrate most of their spend. Nearly 29% of television commercials air to empty rooms. Close to 40% of digital budgets miss their intended audience entirely. These are not fringe estimates — they are the industry’s own measurements of its own waste, largely accepted and quietly absorbed into media plans as the cost of doing business.

Point-of-care advertising produces different results because it operates under entirely different conditions.

Patients exposed to point-of-care advertising are more likely to initiate or refill prescriptions than those who saw the same brand on television. Among patients who notice in-office advertising, 84% are more likely to discuss it with their physician, 68% are more likely to ask about a specific treatment, and 58% do exactly that within the same consultation. Not later. Not after a web search at home. In the room, that day, with their prescriber.

These are not the engagement figures of an undervalued channel. They are the engagement figures of a premium one — currently priced at a fraction of what those outcomes justify.

Pharma knows what it wants — the channel can’t yet prove it can deliver.

Point-of-care revenue surpassed one billion dollars in 2024, up more than 170% between 2019 and 2023. That growth reflects genuine conviction. Pharmaceutical brands have expanded their presence in clinical environments because the intuitive case is overwhelming — no other channel offers comparable context, attention, or proximity to a prescribing decision.

But the nature of that investment has shifted. Brand teams that once allocated to clinical screens on the strength of contextual positioning are now applying the same performance criteria they bring to every other tier-one channel. Audience precision, visit-level targeting, and verifiable impression delivery are no longer differentiators that command a premium. They are the baseline requirements that determine whether a network is considered at all.

What pharmaceutical marketers now require is the ability to reach patients at the precise intersection of condition, care moment, and clinical setting — and to verify, through rigorous post-campaign reporting, that the impressions delivered matched the specifications defined. Proximity to care is no longer sufficient. Proximity plus proof is the new standard.

Clinical screens that cannot demonstrate this level of precision are being evaluated not on what they could deliver, but on what they can currently substantiate. That gap between demonstrable value and actual value is not a permanent feature of the category. It is a structural one — and the networks that move to close it first will define what clinical DOOH commands going forward.

The gap is not about screens — it’s about what the screens can prove

Nothing about this gap requires screen owners to rebuild their networks. The physical infrastructure is correct. The audiences are there. What’s missing is the intelligence layer: a targeting engine that detects a patient check-in signal in real time, matches it against diagnosis-specific campaign criteria, and delivers the contextually appropriate message within a fully HIPAA-compliant framework — without hardware changes, without workflow disruption, without requiring clinical staff to manage anything they don’t already manage.

The capabilities this demands are specific to healthcare in ways that generic ad-tech cannot replicate. HIPAA compliance isn’t an afterthought — it is the foundational constraint around which everything else must be designed. Real-time ad decisioning must operate at the speed of a check-in event, not the speed of a programmatic auction built for consumer retail. Campaign reporting must be rigorous enough to give pharmaceutical brand teams the attribution they need to defend and grow their investment internally.

Screen owners who have not yet connected their inventory to this kind of targeting infrastructure are leaving their networks in the same position they’ve occupied for the past several years: premium environments being evaluated as commodity ones, because the proof of their precision remains unavailable.

Fix the proof problem and the category gets repriced — entirely

The consequence of solving this is not a CPM adjustment. It is a revaluation of the category.

When a patient receives a communication relevant to their specific diagnosis, they walk into their consultation better informed and more likely to raise it with their physician. When a pharmaceutical brand can verify that the impression delivered matched the patient criteria specified, the channel stops being a contextual buy and becomes a performance one — with the accountability structure that justifies meaningful budget growth. When screen owners can offer diagnosis-specific, visit-triggered targeting as a standard capability, the commercial conversation shifts from “we’re in the waiting room” to “we reached your exact patient, at the moment of care, and here’s the evidence.”

Leading pharmaceutical marketers are already beginning to build campaigns from the point of care outward — treating the clinical encounter as the strategic anchor and other media as the amplification layer. The screen networks that can meet that expectation will not just capture a share of a fast-growing budget. They will define the ceiling for what clinical DOOH commands. And that ceiling is substantially higher than where the category sits today.

The inventory was never the limitation. The proof was. And that problem is solvable now.

Photo: Dilok Klaisataporn, Getty Images

This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.